Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.

MLA

Findling, James W., et al. “Late-Night Salivary Cortisol May Be Valuable for Assessing Treatment Response in Patients with Cushing’s Disease: 12-Month, Phase III Pasireotide Study.” Endocrine, vol. 54, no. 2, Nov. 2016, pp. 516–23. EBSCOhost, https://doi.org/10.1007/s12020-016-0978-6.

APA

Findling, J. W., Fleseriu, M., Newell-Price, J., Petersenn, S., Pivonello, R., Kandra, A., Pedroncelli, A. M., & Biller, B. M. K. (2016). Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study. Endocrine, 54(2), 516–523. https://doi.org/10.1007/s12020-016-0978-6

Chicago

Findling, James W, Maria Fleseriu, John Newell-Price, Stephan Petersenn, Rosario Pivonello, Albert Kandra, Alberto M Pedroncelli, and Beverly M K Biller. 2016. “Late-Night Salivary Cortisol May Be Valuable for Assessing Treatment Response in Patients with Cushing’s Disease: 12-Month, Phase III Pasireotide Study.” Endocrine 54 (2): 516–23. doi:10.1007/s12020-016-0978-6.